| BASILEA N |
| Datum/Vreme | / |
| Promena / Promena(%) | - / |
| Tražnja | - |
| Ponuda | - |
| Cena na otvaranju | - |
| Prethodno zatvaranje | - |
| Najviša cena | - |
| Najniža | - |
| Obim [CHF] | - |
| Obim [Jedinice] | |
| Dogovorena cena | |
| ISIN | CH0011432447 |
| Simbol | BSLN |
| Berza | SIX Swiss Exchange |
| Vrsta | Stock |
Druge berze
| Berza | Poslednja cena | Obim | |
|---|---|---|---|
| SIX Swiss Ex.. | 32,800 |  |
499 |
| Lang & Schwa.. | 31,60 | |
|
| Cboe Europe .. | 32,30 | 1.300 | |
| Cboe Europe .. | 32,30 | 700 | |
| Turquoise | 32,35 |  |
593 |
| London Domes.. | 32,35 | 319 | |
| Nasdaq Other.. | 41,0000 | 40 | |
| München | 32,300 | 0 | |
| Berlin | 32,100 | 0 | |
| Frankfurt | 32,2800 | 0 | |
| gettex | 32,340 | ||
| TradeGate | 30,300 | 33 | |
| EUREX | Opcije | ||
Vesti
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
08.03.2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
15.02.2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
24.01.2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
13.01.2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
11.01.2022 / 07:15 - GlobeNewswire
Realno vreme